SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

The reported multibillion-dollar Binance hack is driving concern about exchange security and possible selling pressure across crypto, alongside discussion of Ethereums weakness. Traders are divided between treating the selloff as a buying opportunity and expecting further downside as confidence and market sentiment remain strained.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas pullback amid broader crypto weakness dominates discussion, with traders also voicing concern that the reported Binance security incident could undermine confidence across the market. Some view the decline as a buying-and-staking opportunity, while others point to bearish momentum and warn of further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure after weak Big Tech earnings and renewed doubts that heavy AI spending will generate sufficient returns, with traders debating whether the selloff marks a deeper tech correction or a temporary dip. Speculation about Iran talks and falling oil prices is also fueling hopes for a rebound, while others warn it could be a bear trap.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on a volatile rebound after a sharp selloff, with traders linking the move to falling oil and hopes for progress in U.S.-Iran talks, including a possible reopening of the Strait of Hormuz. Some see a relief rally, while others doubt the reports and warn that midterm uncertainty and concerns about AI-related tech valuations could keep markets choppy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating U.S.-Iran tensions and reported attacks threatening oil flows through the Strait of Hormuz are driving attention to USO and keeping crude prices elevated. Traders are divided between expecting further supply disruption and higher oil prices, and betting that diplomatic progress or a ceasefire could quickly unwind the geopolitical risk premium.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is the dominant focus, with traders debating whether strong AI-driven growth and guidance can meet expectations already viewed as exceptionally high. Bulls anticipate another beat, while skeptics point to the stocks rich valuation and recent AI-sector weakness as risks if guidance disappoints or merely meets the bar.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a sharp semiconductor selloff, as investors question whether massive AI infrastructure spending will generate adequate returns; weak Intel guidance and broader tech selling added pressure. Traders are split between fears of an AI-trade unwind and expectations of a rebound, citing strong chip demand and oversold conditions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high ahead of expected Q3 earnings has fueled attention, with traders weighing BRIUMVIs growth and upcoming subcutaneous data against speculation about a buyout and short covering. No acquisition is confirmed, and some traders argue the rally may simply reflect earnings positioning and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report has traders focused on whether the ad-tech business can sustain growth amid concerns about the broader ad market, competition and analyst downgrades. Bulls argue the decline overlooks strong profitability and growth, while bears fear weaker results or guidance could deepen the downturn.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has focused attention on the threat to Precigens PAPZIMEOS and contributed to a sharp after-hours selloff. Traders disagree on how much competition it poses: some see Inovios surgery-free regimen as an advantage, while others point to Precigens first-mover position, established sales, and full approval.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stay Ahead of the Game With McKesson (MCK) Q2 Earnings: Wall Street's Insights on Key Metrics

Besides Wall Street's top-and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?

Becton Dickinson (BDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why McKesson (MCK) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why McKesson (MCK) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's How Much $100 Invested In McKesson 5 Years Ago Would Be Worth Today

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 25.96% on an annualized basis producing an average annual return of 36.71%. Currently, McKesson has a market capitalization of $118.03 billion.read more...

McKesson (MCK) Stock Dips While Market Gains: Key Facts

The latest trading day saw McKesson (MCK) settling at $1, representing a -1.42% change from its previous close.

Is Trending Stock McKesson Corporation (MCK) a Buy Now?

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson Corporation Declares Quarterly Dividend

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 94 cents per share of common stock. The dividend will be payable on January 4, 2027, to shareholders of record on December 1, 2026. About McKesson Corporation McKesson Corporation is a diversified...

McKesson (MCK) Outperforms Broader Market: What You Need to Know

In the latest trading session, McKesson (MCK) closed at $1, marking a +1.95% move from the previous day.

McKesson Corp. engages in providing healthcare services. It operates through the following segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions. The North American Pharmaceutical segment focuses on distribution of branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs to customers in U.S. and Canada. The Oncology and Multispecialty segment includes provision of solutions that includes specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, InspiroGene cell and gene therapy services, technology solutions, practice consulting services, and vaccine distribution. The RxTS segment focuses on solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Mckesson Corporation

OPCH Stock Soars 22% After-Hours On $5B McKesson Buyout Talks

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>A deal could be reached as soon as Tuesday, though nothing is signed and the talks could still collapse, FT added.&nbsp;</li><li>Under the terms being discussed, CD&amp;R would own 51% through a joint venture and McKesson 49%, with McKesson holding a right to buy the buyout firm’s stake later, the paper said.</li><li>The bid lands after a soft stretch for Option Care: in late July, the company narrowed full-year guidance to $5.675 billion to $5.775 billion of revenue and adjusted earnings of $1.85 to $1.92 a share.</li></ul><p>Option Care Health (OPCH) shares jumped about 22% in after-hours trading on Monday after a report that McKesson (MCK) and private equity firm Clayton Dubilier &amp; Rice are closing in on a buyout worth more than $5 billion, including debt.</p><p><a class="mention" data-mention="$OPCH" data-symbol-id="OPCH" href="https://stocktwits.com/symbol/OPCH" target="_blank">OPCH shares</a> closed up 3% on Monday, giving the company a market capitalization of about $3.5 billion. Including debt, the company has an enterprise value of $4.7 billion.</p><p>Healthcare firm McKesson, in comparison, has a market value of about $107 billion.</p><h2 class="st-heading-2">OPCH-MCK Talks Not Yet Signed</h2><p>Option Care, the largest independent U.S. provider of medical infusion services, is in advanced talks after a joint bid, people familiar with the matter told the Financial Times. A deal could be reached as soon as Tuesday, though nothing is signed and the talks could still collapse, it added.</p><p>Under the terms being discussed, CD&amp;R would own 51% through a joint venture and McKesson 49%, with McKesson holding a right to buy the buyout firm’s stake later, the paper said.</p><h2 class="st-heading-2">A Fit With Oncology And Home Care</h2><p>Option Care last year treated more than 315,000 patients who need specialty drugs by infusion for cancer, autoimmune disease and serious infections, either at home or at 184 centers. Hospital infusion is expensive, and more complex biologic drugs can only be given that way, which has supported the business.</p><p>For McKesson, the network would sit alongside its drug-distribution core and its chemotherapy and cancer-care clinics, one of the faster-growing parts of a company with about $403 billion in annual revenue. In August, McKesson agreed to buy Precision Medicine Group for about $2.25 billion to deepen clinical research and commercialization services.</p><p>The bid lands after a soft stretch for Option Care. In late July, the company reported second-quarter revenue of $1.44 billion, up 1.9% from a year earlier, and narrowed full-year guidance to $5.675 billion to $5.775 billion of revenue and adjusted earnings of $1.85 to $1.92 a share. Management said one long-running therapy weighed on results, even as short-term infusions and some rare-disease treatments held steady.</p><h2 class="st-heading-2">How Did OPCH, MCK Retail Traders React?</h2><p>On Stocktwits, retail sentiment around OPCH stock jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.</p><p>Meanwhile, sentiment around MCK stayed within ‘neutral’ levels.</p><p>While OPCH has lost 27% year-to-date, MCK has gained 12%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-ends-higher-on-starship-fuel-plans-analyst-optimism-and-tsmc-talks/cZDqBUNRBjY">SPCX Stock Ends Higher On Starship Fuel Plans, Analyst Optimism And TSMC Talks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Option Care is in advanced talks after a joint bid from McKesson and private equity firm Clayton Dubilier & Rice, FT reported. 

Option Care Health Inc. - Registered Shares

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$MCK Hilarious, predictable and somehow consoling.  When its risk on, down....shit goes sideways, you should be glad you have it. Won't make me rich, but will insulate against implosion. That's the plan, working so far.

Chris

$MCK AI efficiency isn't even the REAL growth driver... Oncology and data services in that order.

TICKERTUTOR

Sell alert on $MCK this morning. 
 
Alert said buy Oct 28 after the close at $960.56, sell today at $1002.55. +4.37%, 2 trading days. 
 
I post every alert with its result, losers included.

Picckles

education tie in. $MCK is flat premarket while option care, the company it is reported to be buying into with cd&r, is up about 33%. an unsigned deal report prices a probability, not a deal price. if talks fail the gap can disappear, and the buyer barely moves either way. as of this morning no agreement has been signed.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MCK Mckesson Corporation

Fundamentals

Latest MCK News